QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 heartbeam-q2-eps-015-inline
HeartBeam Q2 EPS $(0.15), Inline
08/13/2025 20:02:05

HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 21.0...

 heartbeam-to-share-cardiac-tech-vision-with-investors-at-iaccess-alpha-summer-conference

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personal...

 heartbeam-q1-eps-018-misses-015-estimate

HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) b...

 heartbeam-announces-it-has-received-two-new-us-patents

First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the...

 heartbeams-synthesized-12-lead-electrocardiogram-meets-clinical-endpoints-in-valid-ecg-pivotal-study

Milestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 20...

 heartbeam-and-accurkardia-enters-strategic-collaboration-to-advance-cardiac-monitoring-innovation

Collaboration brings together two leaders in ambulatory ECG recording and analysisHeartBeam, Inc. (NASDAQ:BEAT), a medical tech...

 heartbeam-q4-2024-adj-eps-073-misses-019-estimate

HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.19) b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION